Science Explorer Back to mapMap
Discussion
Topic · Endocrinology, Diabetes and Metabolism

Diabetes, Cardiovascular Risks, and Lipoproteins

Diabetes, Cardiovascular Risks, and Lipoproteins is a research topic within Endocrinology, Diabetes and Metabolism. Science Explorer counts 60k research works in it since 1950. 9.9% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the metabolic syndrome, its association with cardiovascular disease, diabetes, insulin resistance, obesity, and atherosclerosis. It includes studies on glucose metabolism, lifestyle interventions, and global prevalence of related conditions.

  • Metabolic Syndrome
  • Cardiovascular Disease
  • Diabetes
  • Insulin Resistance
  • Obesity
  • Glucose Metabolism
  • Atherosclerosis
  • Lifestyle Intervention
  • Cholesterol
  • Global Prevalence
Research works
60k
fractional, since 1950
In the world top 10%
6k
per year above
Top-10% rate
9.9%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+20%
the tick is no change
Largest producer
China
33% of the 10 largest, 2022-now
Diabetes, Cardiovascular Risks, and Lipoproteins

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Diabetes, Cardiovascular Risks, and Lipoproteins research?

By volume, China and the United States publish the most (2.7k and 1.8k works in 2022-now).

By volume, 2022-now

  1. 1 China 2.7k works
  2. 2 United States 1.8k works
  3. 3 India 1k works
  4. 4 Indonesia 560 works
  5. 5 United Kingdom 445 works
  6. 6 South Korea 385 works
  7. 7 Japan 381 works
  8. 8 Iran 339 works
  9. 9 Spain 306 works
  10. 10 Italy 277 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

China: 33.1%United States: 22.3%India: 12.1%Indonesia: 6.8%6 others listed: 25.8%33%largest
China2,738 · 33.1%United States1,844 · 22.3%India1,002 · 12.1%Indonesia560 · 6.8%6 others listed2,132 · 25.8%

Shares of the rows listed above, not of the whole node.

Which institutions lead Diabetes, Cardiovascular Risks, and Lipoproteins research?

By volume in 2022-now, Capital Medical University publishes the most Diabetes, Cardiovascular Risks, and Lipoproteins research, followed by Harvard University and Chinese Academy of Medical Sciences & Peking Union Medical College.

By volume, 2022-now

  1. 1 Capital Medical UniversityChina 92 works
  2. 2 Harvard UniversityUnited States 88 works
  3. 3 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 88 works
  4. 4 Shanghai Jiao Tong UniversityChina 73 works
  5. 5 Nanjing Medical UniversityChina 67 works
  6. 6 Peking UniversityChina 66 works
  7. 7 Sun Yat-sen UniversityChina 62 works
  8. 8 Sichuan UniversityChina 61 works
  9. 9 Central South UniversityChina 55 works
  10. 10 All India Institute of Medical SciencesIndia 53 works

Who are the leading researchers in Diabetes, Cardiovascular Risks, and Lipoproteins?

The most-cited researchers publishing on Diabetes, Cardiovascular Risks, and Lipoproteins include Douglas G. Altman, Christopher J L Murray and Eric S. Lander.

  1. 1 Douglas G. Altman United Kingdom 862k citations
  2. 2 Christopher J L Murray United States 583k citations
  3. 3 Eric S. Lander United States 524k citations
  4. 4 Simon Iain Hay United States 452k citations
  5. 5 Theo Vos United States 439k citations
  6. 6 George Davey Smith United Kingdom 435k citations
  7. 7 Ali H. Mokdad United States 429k citations
  8. 8 Walter Churchill Willett United States 411k citations
  9. 9 Mark J. Daly United States 403k citations
  10. 10 Stacey L. Gabriel United States 402k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Diabetes, Cardiovascular Risks, and Lipoproteins?

The most cited paper in Diabetes, Cardiovascular Risks, and Lipoproteins is "Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge" (William T. Friedewald, Robert I. Levy, Donald S. Fredrickson, 1972), with 32,670 citations. Next come "Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin" (19,192) and "Global Prevalence of Diabetes" (15,370).

Most cited papers
#PaperReleasedCitations
1 Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge William T. Friedewald, Robert I. Levy, Donald S. Fredrickson · Clinical Chemistry Jun 1972 32,670
2 Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin Diabetes Prevention Program Research Group · New England Journal of Medicine Open access 7 Feb 2002 19,192
3 Global Prevalence of Diabetes Sarah H. Wild, Gojka Roglić, Anders Green et al. · Diabetes Care May 2004 15,370
4 Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation K. G. M. M. Alberti, Paul Zimmet, WHO Consultation · Diabetic Medicine Jul 1998 15,336
5 Harmonizing the Metabolic Syndrome K. G. M. M. Alberti, Robert H. Eckel, Scott M. Grundy et al. · Circulation Open access 5 Oct 2009 14,957
All 98 most cited papers, with filters and sorting

Where is Diabetes, Cardiovascular Risks, and Lipoproteins research done?

The largest centres of Diabetes, Cardiovascular Risks, and Lipoproteins research in 2022-now are Beijing (China), Seoul (South Korea), Shanghai (China) and Guangzhou (China). Among places with at least 20 works in it, it is an unusually large share of all research in Tangshan.

Largest cities, 2022-now

  1. 1 BeijingChina 426 works
  2. 2 SeoulSouth Korea 229 works
  3. 3 ShanghaiChina 187 works
  4. 4 GuangzhouChina 173 works
  5. 5 TehranIran 155 works
  6. 6 LondonUnited Kingdom 135 works
  7. 7 NanjingChina 121 works
  8. 8 TokyoJapan 99 works
  9. 9 ChengduChina 97 works
  10. 10 New DelhiIndia 95 works

Where it is the local speciality

  1. TangshanCN · 30.3 works9.5×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Diabetes, Cardiovascular Risks, and Lipoproteins than the world average.

See Diabetes, Cardiovascular Risks, and Lipoproteins on the map

Where is the best place to study Diabetes, Cardiovascular Risks, and Lipoproteins?

Among universities, judged by research, University of Copenhagen, Chinese Academy of Medical Sciences & Peking Union Medical College and Harvard University score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%mean 24%fractional works in this field (log) →share of work in the world top 10% →Nanchang UniversityUniversity of Copenh…Chinese Academy of M…Harvard University
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Citation excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1University of CopenhagenDenmark 79.224.8%4.5×49 +15.2%
2Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 76.819.4%7.3×88 +130.5%
3Harvard UniversityUnited States 76.519.1%2.4×88 +2.4%
4Nanchang UniversityChina 74.127.4%3.7×32 +281.6%
5Capital Medical UniversityChina 72.616.5%7.6×92 +106.8%
6Beijing University of Chinese MedicineChina 72.429.5%7.8×21 +571.8%
7University of California San DiegoUnited States 69.628.9%1.9×21 +48.9%
8Wenzhou Medical UniversityChina 69.225.1%5.9×34 +172.7%
9Sichuan UniversityChina 66.921.2%2.3×60 +140.9%
10Shantou UniversityChina 65.928.1%5.5×14 +243.3%

Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Diabetes, Cardiovascular Risks, and Lipoproteins, country by country

Is Diabetes, Cardiovascular Risks, and Lipoproteins research growing?

Output in 2022-2025 was 20% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Diabetes, Cardiovascular Risks, and Lipoproteins.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Diabetes, Cardiovascular Risks, and Lipoproteins as a percentage of every work published that year, 0.051% in 2024.

still counting0.025%0.050%0.075%Diabetes, Cardiovascular Risks, and Lipoproteins0.060% in 202519801990200020102020

Fractional works of Diabetes, Cardiovascular Risks, and Lipoproteins over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Diabetes, Cardiovascular Risks, and Lipoproteins10.0% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Diabetes, Cardiovascular Risks, and Lipoproteins. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.